Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy: A multicentre study in epilepsy clinics in the United Kingdom (UK)

Flores, Lorena; Kemp, Steven; Colbeck, Katie; Moran, Nicholas; Quirk, Jennifer; Ramkolea, Pierre; Oertzen, Tim J. von; Nashef, Lina; Richardson, Mark P.; Goulding, Peter; Elwes, Robert

doi:10.1016/j.seizure.2012.05.005

Cited by 52 publications

(51 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Retention rates of 79.4% at 3 months and 75.8% at 6 months are comparable with other AEDs licensed in the last decade, such as lacosamide (80% at 6 months, 62–68% at 1 year), zonisamide (62% at 1 year), perampanel (60% at 6 months), or eslicarbazepine acetate (80–82% at 6 months, 72% at 1 year) . We observed a rather stable withdrawal rate over 12 months, at least in the patients without prior LEV, in comparison to the asymptotic curve with decreasing withdrawal rates reported for other AEDs in retention studies .…”

Section: Discussionsupporting

confidence: 83%

Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany

et al. 2017

View full text Add to dashboard Cite

BRV in broad clinical postmarketing use is a well-tolerated anticonvulsant drug with 50% responder rates, similar to those observed in the regulatory trials, even though 90% of the patients included had previously been exposed to LEV. An immediate switch from LEV to BRV at a ratio of 10:1 to 15:1 is feasible. The only independent significant predictor of efficacy was the start of BRV in patients not currently taking LEV. The occurrence of BAE during previous LEV exposure predicted poor psychobehavioral tolerability of BRV treatment. A switch to BRV can be considered in patients with LEV-induced BAE.

show abstract

Section: Discussionsupporting

confidence: 83%

Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Concerning the influence of concomitant SCB use, several randomized, placebo‐controlled, double‐blind, and postmarketing observational trials have been conducted. Of these trials, some, including the abovementioned studies by Flores et al and Novy et al, did not notice an interaction between LCM and concomitant AED use. The primary focus of such trials was to evaluate the efficacy of LCM .…”

Section: Discussionmentioning

confidence: 97%

Lacosamide in the treatment of patients with epilepsy and intellectual disabilities: A long‐term study of 136 patients

2017

View full text Add to dashboard Cite

One of the major challenges in medically caring for patients with epilepsy and IDs is the high rate of drug resistance. However, there is a lack of evidence-based information about the efficacy and tolerability of AEDs in this population. It has been shown that concomitant SCB use is a key factor in increasing the risk of LCM failure in children with epilepsy. This finding has not been replicated in our predominantly adult sample of patients with IDs.

show abstract

“…Most patients (86.9%) presented symptomatic partial epilepsy and 80% were taking two or more antiepileptic drugs when lacosamide was introduced to the treatment (mean 2, range 0-4). Retention rates were 80% at 6 months, 68% at 1 year, and 45% at 2 years (Flores et al, 2012). Lamotrigine clearance in older adults was lower compared to younger adults in patients receiving polytherapy, polytherapy without enzyme inducers, or valproate.…”

Section: Retention Ratesmentioning

confidence: 93%

Treatment gaps of epilepsy and retention rates of sodium valproate in rural Guangxi, China

et al. 2014

View full text Add to dashboard Cite

ABSTRACT. This study aimed to investigate the prevalence and treatment gaps of epilepsy, as well as the clinical effects, drug safety, and retention rates of sodium valproate (VPA) for treating epilepsy. Physicians received supervised training to use the survey form recommended by the Chinese Association Against Epilepsy while screening for suspected or confirmed epilepsy cases. These cases were ultimately enrolled in the study by neurologists. Enrolled patients were given a year of free VPA treatment so that its efficacy and adverse effects during the follow-up period could be evaluated. In total, 302 patients were enrolled in this study, which included 189 males and 113 females. Among these cases, 179 (59.27%) were confirmed to have generalized seizures, 162 (53.6%) had tonic-clonic seizures, 10 (3.3%) had absence seizures, and 123 (40.72%) had partial seizures. Only 63 patients had received regular treatments 1 week before enrollment, with a treatment gap of 79.1%. The retention rates during the 6th, 12th, 18th, and 24th months were 100, 93.56, 89.05, and 77.06%, respectively. During the 1-year follow-up period, 30 cases encountered mild adverse effects, but no severe adverse reactions were reported. A large treatment gap for epilepsy still existed in the rural areas of southern China, with few adverse effects and high

show abstract

Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy: A multicentre study in epilepsy clinics in the United Kingdom (UK)

Abstract: LCS appears to be an effective and safe AED when used as adjunctive therapy in patients with refractory partial epilepsy.

Cited by 52 publications

References 20 publications

Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany

Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany

Lacosamide in the treatment of patients with epilepsy and intellectual disabilities: A long‐term study of 136 patients

Treatment gaps of epilepsy and retention rates of sodium valproate in rural Guangxi, China

Contact Info

Product

Resources

About